What is OnKure Therapeutics, Inc.'s earnings per share (EPS)?

OnKure Therapeutics, Inc. (OKUR) reported diluted earnings per share of -$4.40 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

OnKure Therapeutics, Inc. (OKUR) Financials

OKUR

Trailing 12 months to June 30, 2026

Net Income -$58.7M +2.7% YoY

EPS (Diluted) -$4.40 FY2025 annual

Free Cash Flow -$47.9M +22.0% YoY

Operating Cash Flow -$47.8M +21.9% YoY

Market Cap $97.6M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.6x on $172.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OKUR SEC filings page.

This page shows OnKure Therapeutics, Inc. (OKUR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OKUR FY2025 2026-10-03

OnKure operates as a development-stage biotech, with R&D-driven losses funded mainly by prior financing rather than operating revenue.

In FY2025, operating cash outflow of $51.8M nearly matched free cash flow of -$51.9M, while capital expenditures were only $46K; cash use is overwhelmingly operational, not driven by building a heavy physical asset base. The supplied liquidity measure equaled 13.7 months of reported annual operating outflow, linking the balance of cash and investments to the scale of that spending.

R&D increased from $43.8M in FY2024 to $48.3M in FY2025 as the operating loss widened from $54.4M to $63.0M. With no usable revenue figure in either period, the statements describe a company still converting research spending into losses rather than sales.

FY2024 financing of $116.1M helped lift assets to $114.9M, but FY2025 financing was only $163K and assets fell to $62.1M. The balance sheet therefore depends on periodic capital raising; low reported liabilities of $5.9M indicate the pressure is funding availability rather than debt-heavy financing.

Financial Health Signals

Financial health score not available

OnKure Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/5

OnKure Therapeutics, Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

OnKure Therapeutics, Inc. reported a net loss of $59.5M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

OnKure Therapeutics, Inc. reported an operating loss of $63.0M against $3.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$16.8M

YoY-3.7%

QoQ-8.4%

OnKure Therapeutics, Inc.'s EBITDA was -$16.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.7% from the same quarter a year earlier. Against the prior quarter it is down 8.4%.

Net Income

-$15.3M

YoY+0.3%

QoQ-1.2%

OnKure Therapeutics, Inc. reported -$15.3M in net income in Q2 2026. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.

EPS (Diluted)

-$0.31

OnKure Therapeutics, Inc. earned -$0.31 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$10.4M

YoY+22.1%

QoQ+20.0%

OnKure Therapeutics, Inc. recorded an outflow of $10.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 22.1% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.

Cash & Debt

$166.5M

YoY+99.7%

QoQ-13.3%

5Y CAGR+3.5%

OnKure Therapeutics, Inc. held $166.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

40M

OnKure Therapeutics, Inc. had 40M shares outstanding in Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-8.9%

YoY+10.8pp

QoQ-0.7pp

OnKure Therapeutics, Inc.'s ROE was -8.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 10.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$12.6M

YoY0.0%

QoQ+7.7%

OnKure Therapeutics, Inc. invested $12.6M in research and development in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 7.7%.

Capital Expenditures

$3K

YoY-76.9%

QoQ-40.0%

5Y CAGR-12.9%

OnKure Therapeutics, Inc. invested $3K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 76.9% from the same quarter a year earlier. Against the prior quarter it is down 40.0%.

Share Buybacks

Not reported for Q2 2026.

OKUR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OKUR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	$0	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$48.3M+10.2%	$43.8M+36.4%	$32.1M-14.8%	$37.7M+33.9%	$28.2M+76.7%	$15.9M
SG&A Expenses	N/A	$14.7M+38.7%	$10.6M+119.8%	$4.8M-70.1%	$16.1M+38.6%	$11.6M+222.9%	$3.6M
Operating Income	N/A	-$63.0M-15.7%	-$54.4M-47.3%	-$36.9M+31.4%	-$53.8M-35.2%	-$39.8M-103.7%	-$19.6M
EBITDA	N/A	-$62.5M-15.9%	-$53.9M-47.7%	-$36.5M+32.1%	-$53.8M-35.2%	-$39.8M-103.8%	-$19.5M
Interest Expense	N/A	$3.4M+100.4%	$1.7M+5.5%	$1.6M	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0
Net Income	-$58.7M	-$59.5M-13.0%	-$52.7M-49.2%	-$35.3M+32.0%	-$52.0M-30.6%	-$39.8M-104.3%	-$19.5M
EPS (Basic)	N/A	-$4.40+71.2%	-$15.28+87.7%	-$124.41-5768.4%	-$2.12+3.2%	-$2.19+77.2%	-$9.60
EPS (Diluted)	—	-$4.40	-$15.28	-$124.41	-$2.12+3.2%	-$2.19	-$9.60
Diluted Shares (Avg)	N/A	14M	3M	283,817	24M+35.0%	18M	2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q
R&D Expenses	$12.6M0.0%	$11.7M-10.0%	N/A	$11.9M+17.8%	$12.6M+17.3%	$13.0M+51.9%	N/A	$10.1M-25.7%
SG&A Expenses	$4.3M+15.5%	$3.9M-2.0%	N/A	$3.6M+156.9%	$3.7M+3.3%	$4.0M+215.3%	N/A	$1.4M-80.8%
Operating Income	-$16.9M-3.5%	-$15.6M+8.1%	N/A	-$15.5M-34.7%	-$16.3M-13.8%	-$17.0M-72.9%	N/A	-$11.5M+44.9%
EBITDA	-$16.8M-3.7%	-$15.5M+8.1%	N/A	-$15.4M-35.1%	-$16.2M-13.9%	-$16.9M-73.7%	N/A	-$11.4M+45.3%
Interest Expense	$1.6M+66.3%	$458K-57.4%	N/A	$802K+1922.7%	$934K+357.8%	$1.1M	N/A	-$44K
Net Income	-$15.3M+0.3%	-$15.2M+4.8%	-$13.5M+22.6%	-$14.7M-27.2%	-$15.4M-8.8%	-$15.9M-67.0%	-$17.4M	-$11.6M+39.8%
EPS (Basic)	-$0.31+72.8%	-$1.11+6.7%	-$0.99+90.1%	-$1.09+97.0%	-$1.14+97.5%	-$1.19+96.1%	-$10.05+90.5%	-$36.55-543.5%
EPS (Diluted)	-$0.31	-$1.11+6.7%	-$0.99	-$1.09	-$1.14	-$1.19	-$10.05+90.5%	-$36.55
Diluted Shares (Avg)	50M	14M+1.9%	N/A	14M	14M	13M	N/A	316,142

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

OKUR Balance Sheet

OKUR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$62.1M-45.9%	$114.9M+221.6%	$35.7M-67.0%	$108.2M-29.8%	$154.0M+178.9%	$55.2M
Current Assets	$60.8M-46.2%	$113.0M+234.7%	$33.8M-68.3%	$106.4M-30.8%	$153.7M+179.4%	$55.0M
Cash & Equivalents	$59.0M-46.7%	$110.8M+270.7%	$29.9M+49.9%	$19.9M-84.0%	$124.7M+132.5%	$53.6M
Short-Term Investments	$0	$0	$0-100.0%	$81.2M+253.1%	$23.0M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.9M-46.4%	$11.1M-91.9%	$137.6M-15.4%	$162.6M+2286.6%	$6.8M-93.0%	$97.3M
Current Liabilities	$5.9M-43.8%	$10.5M+44.5%	$7.3M+2.3%	$7.1M+14.9%	$6.2M+35.4%	$4.6M
Non-Current Liabilities	$12K-97.8%	$549K-99.6%	$130.3M-16.2%	$155.5M+25346.2%	$611K-99.3%	$92.8M
Total Equity	$56.2M-45.9%	$103.8M+202.0%	-$101.8M-87.1%	-$54.4M-137.0%	$147.2M+449.5%	-$42.1M
Retained Earnings	-$214.2M-38.5%	-$154.7M-51.6%	-$102.1M+25.3%	-$136.7M-61.3%	-$84.7M-88.5%	-$45.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q
Total Assets	$179.4M+108.4%	$198.7M+98.9%	$62.1M-45.9%	$72.8M-6.2%	$86.1M+9.3%	$99.9M+18.0%	$114.9M+221.6%	$77.6M-40.5%
Current Assets	$177.7M+110.1%	$197.5M+101.2%	$60.8M-46.2%	$71.5M-7.1%	$84.6M+8.4%	$98.2M+17.0%	$113.0M+234.7%	$77.0M-40.2%
Cash & Equivalents	$166.5M+99.7%	$192.1M+98.7%	$59.0M-46.7%	$70.3M+15.9%	$83.4M+131.8%	$96.7M+374.4%	$110.8M+270.7%	$60.7M+417.1%
Short-Term Investments	$9.9M	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0	$16.0M-86.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.2M-8.3%	$14.3M+55.3%	$5.9M-46.4%	$6.4M-97.0%	$7.9M-96.1%	$9.2M-95.3%	$11.1M-91.9%	$212.7M+1277.2%
Current Liabilities	$6.6M-12.6%	$14.3M+63.1%	$5.9M-43.8%	$6.2M+92.3%	$7.6M+463.6%	$8.8M+212.2%	$10.5M+44.5%	$3.2M-76.1%
Non-Current Liabilities	$602K+96.1%	$12K-97.3%	$12K-97.8%	$160K-99.9%	$307K-99.8%	$449K-99.8%	$549K-99.6%	$209.4M+11034.9%
Total Equity	$172.1M+120.2%	$184.4M+103.4%	$56.2M-45.9%	$66.4M+149.2%	$78.2M+163.3%	$90.6M+181.5%	$103.8M+202.0%	-$135.1M-217.5%
Retained Earnings	-$244.7M-31.6%	-$229.4M-34.4%	-$214.2M-38.5%	-$200.7M+14.9%	-$186.0M+19.9%	-$170.6M+24.8%	-$154.7M-51.6%	-$236.0M-23.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

OKUR Cash Flow Statement

OKUR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$47.8M	-$51.8M-1.4%	-$51.1M-48.0%	-$34.5M+27.1%	-$47.4M-24.7%	-$38.0M-104.9%	-$18.5M
Depreciation & Amortization	N/A	$447K-2.6%	$459K+10.1%	$417K+373.9%	$88K+76.0%	$50K+35.1%	$37K
Stock-Based Compensation	N/A	$11.6M+156.8%	$4.5M+2176.4%	$199K-95.4%	$4.3M+11.0%	$3.9M+890.1%	$393K
Capital Expenditures	$23K	$46K-11.5%	$52K-78.9%	$246K-28.9%	$346K+74.7%	$198K+725.0%	$24K
Free Cash Flow	-$47.9M	-$51.9M-1.4%	-$51.2M-47.1%	-$34.8M+27.1%	-$47.7M-25.0%	-$38.2M-105.7%	-$18.6M
Investing Cash Flow	-$9.9M	-$46K-100.3%	$15.9M+6552.4%	-$246K+99.6%	-$57.8M-147.4%	-$23.4M-416.9%	$7.4M
Financing Cash Flow	$140.9M	$163K-99.9%	$116.1M+118.6%	$53.1M+11179.2%	$471K-99.6%	$132.4M+180.1%	$47.3M
Dividends Paid	N/A	N/A	$0	$0	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$4.4M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q
Operating Cash Flow	-$10.4M+22.0%	-$12.9M+7.6%	-$11.5M+50.7%	-$13.0M-22.3%	-$13.3M-105.1%	-$14.0M-31.8%	-$23.4M-348.9%	-$10.7M+43.2%
Depreciation & Amortization	$87K-25.6%	$104K-11.9%	$104K-10.3%	$108K-5.3%	$117K+1.7%	$118K+3.5%	$116K-60.1%	$114K+165.1%
Stock-Based Compensation	$3.0M+4.8%	$2.8M+1.3%	N/A	$3.0M+3745.5%	$2.9M+60.4%	$2.7M+2465.4%	N/A	$77K-94.6%
Capital Expenditures	$3K-76.9%	$5K-72.2%	$9K-40.0%	$6K-66.7%	$13K+30.0%	$18K+100.0%	$15K-70.0%	$18K-5.3%
Free Cash Flow	-$10.4M+22.1%	-$12.9M+7.7%	-$11.5M+50.7%	-$13.0M-22.1%	-$13.3M-105.0%	-$14.0M-31.8%	-$23.4M-350.4%	-$10.7M+43.2%
Investing Cash Flow	-$9.9M-75823.1%	-$5K+72.2%	-$9K-100.1%	-$6K+66.7%	-$13K-30.0%	-$18K-100.0%	$15.9M-45.2%	-$18K-100.1%
Financing Cash Flow	-$5.4M	$146.0M+189709.1%	$240K-99.8%	$0-100.0%	$0-100.0%	-$77K-870.0%	$110.2M+1028.9%	$5K-97.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

OKUR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OKUR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	-105.9%-55.2pp	-50.7%	N/A	N/A	-27.0%	N/A
Return on Assets	-95.8%-50.0pp	-45.8%+53.0pp	-98.8%-50.8pp	-48.0%-22.2pp	-25.8%+9.4pp	-35.3%
Current Ratio	10.28-0.5x	10.73+6.1x	4.63-10.3x	14.93-9.9x	24.79+12.8x	12.01
Debt-to-Equity	0.110.0x	0.11	N/A	N/A	0.05	N/A
Asset Turnover	N/A	0.00	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q
Return on Equity	-8.9%+10.8pp	-8.2%+9.3pp	-24.0%-7.2pp	-22.1%	-19.7%	-17.6%	-16.8%	N/A
Return on Assets	-8.6%+9.3pp	-7.6%+8.3pp	-21.7%-6.6pp	-20.2%-5.3pp	-17.9%+0.1pp	-15.9%-4.7pp	-15.2%	-14.9%-0.2pp
Current Ratio	26.75+15.6x	13.78+2.6x	10.28-0.5x	11.45-12.3x	11.13-46.7x	11.18-18.6x	10.73+6.1x	23.71+14.2x
Debt-to-Equity	0.04-0.1x	0.080.0x	0.110.0x	0.10	0.10	0.10	0.11	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
OnKure Therapeutics, Inc. OKUR	FY2025	N/A	-$59.5M	N/A	$97.6M	—
AN2 Therapeutics, Inc. ANTX	FY2025	N/A	-$35.2M	N/A	$166.0M	—
Iterum Therapeutics plc ITRM	FY2025	N/A	-$24.8M	N/A	$1.6M	—
Kezar Life Sciences, Inc. KZR	FY2025	$0	-$56.0M	N/A	$53.9M	—
Estrella Immunopharma, Inc. ESLA	FY2025	N/A	-$13.1M	N/A	$17.8M	—
Mersana Therapeutics, Inc. MRSN	FY2024	$40.5M	-$69.2M	N/A	$145.4M	54/100

Where OnKure Therapeutics, Inc. Ranks

Frequently Asked Questions

Is OnKure Therapeutics, Inc. profitable?

No, OnKure Therapeutics, Inc. (OKUR) reported a net income of -$59.5M in fiscal year 2025.

What is OnKure Therapeutics, Inc.'s EBITDA?

OnKure Therapeutics, Inc. (OKUR) had EBITDA of -$62.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is OnKure Therapeutics, Inc.'s return on equity (ROE)?

OnKure Therapeutics, Inc. (OKUR) has a return on equity of -105.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is OnKure Therapeutics, Inc.'s free cash flow?

OnKure Therapeutics, Inc. (OKUR) recorded an outflow of $51.9M in free cash flow during fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is OnKure Therapeutics, Inc.'s operating cash flow?

OnKure Therapeutics, Inc. (OKUR) recorded an outflow of $51.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are OnKure Therapeutics, Inc.'s total assets?

OnKure Therapeutics, Inc. (OKUR) had $62.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are OnKure Therapeutics, Inc.'s capital expenditures?

OnKure Therapeutics, Inc. (OKUR) invested $46K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does OnKure Therapeutics, Inc. spend on research and development?

OnKure Therapeutics, Inc. (OKUR) invested $48.3M in research and development during fiscal year 2025.

How many shares does OnKure Therapeutics, Inc. have outstanding?

OnKure Therapeutics, Inc. (OKUR) had 14M shares outstanding as of fiscal year 2025.

What is OnKure Therapeutics, Inc.'s current ratio?

OnKure Therapeutics, Inc. (OKUR) had a current ratio of 10.28 as of fiscal year 2025, which is generally considered healthy.

What is OnKure Therapeutics, Inc.'s debt-to-equity ratio?

OnKure Therapeutics, Inc. (OKUR) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is OnKure Therapeutics, Inc.'s return on assets (ROA)?

OnKure Therapeutics, Inc. (OKUR) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is OnKure Therapeutics, Inc.'s P/E ratio?

OnKure Therapeutics, Inc. (OKUR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $97.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is OnKure Therapeutics, Inc.'s price-to-sales ratio?

OnKure Therapeutics, Inc. (OKUR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $97.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does OnKure Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, OnKure Therapeutics, Inc. (OKUR) held $59.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.8M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is OnKure Therapeutics, Inc.'s Piotroski F-Score?

OnKure Therapeutics, Inc. (OKUR) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are OnKure Therapeutics, Inc.'s earnings high quality?

OnKure Therapeutics, Inc. (OKUR) reported a net loss of $59.5M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can OnKure Therapeutics, Inc. cover its interest payments?

OnKure Therapeutics, Inc. (OKUR) reported an operating loss of $63.0M against $3.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.